What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Sclerosing Cholangitis (PSC)
- Main trialPhase 2
- “The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.”In the company’s words, NCT06699121 on ClinicalTrials.gov
Other drugs for Primary Sclerosing Cholangitis (PSC)
- Norucholic acidDr. Falk Pharma GmbH · Phase 3
- ElafibranorIpsen · Phase 3
- MaralixibatMirum Pharmaceuticals, Inc. · Phase 3
- HK-660SCuromeBiosciences · Phase 2
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
- TAK-781Takeda · Phase 1
Coming up1
- Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2028 | A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC | |
| Phase 1Completed | 1 Apr 2022 | A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026